> Australia's ChemGenex Pharmaceuticals has raised A$15 million in capital. Merck Sante and Charter Pacific both participated. Most of the money will go to pipeline development of experimental drugs, including its lead candidate Ceflatonin. Release
> The UK's Vernalis is touting data that indicates that its headache drug Frova would be an effective therapy for menstrual migraine. Report
> Cytogen has agreed to buy out the bone cancer therapy Quadramet from Berlex for $6 million plus stock. Report
> Phytopharm has slipped into the red but is upbeat about ongoing licensing talks. Report
> Chutes & Ladders: PDI has named Michael Marquand as CEO. Article
> Roche Holding has acquired the rights to the heart disease protein component Trimeric Apo A-I. Report
And Finally…The Boston Globe looks at the way nanotechnology is influencing the biotech field. Article